No Data
No Data
Shanghai Kaibao Pharmaceutical (300039.SZ) won the Second Prize of National Science and Technology Progress Award.
On June 24, 2024, the National Science and Technology Achievement Conference of 2023 was held in Beijing, where Shanghai Kaibao Pharmaceutical Co. Ltd., of which Director Mu Jingwei participated, was awarded the second prize of the National Science and Technology Progress Award for "Integrated Innovation and Support System Creation and Application of Traditional Chinese Medicine Quality Detection Technology".
Shanghai Kaibao Pharmaceuticals (300039.SZ) plans to distribute 1 yuan per 10 shares, with ex-right and ex-dividend on June 19.
Shanghai Kaibao Pharmaceutical (300039.SZ) announced that it plans to distribute cash dividends of RMB 1.00 per 10 shares to all shareholders for the 2023 annual equity. The ex-dividend date is June 19, 2024.
Shanghai Kaibao Pharmaceutical (300039.SZ): Not currently involved in using AI for product development.
Shanghai Kaibao (300039.SZ) stated on the investor interaction platform on June 12 that the company is a comprehensive pharmaceutical enterprise mainly engaged in the research and development, production, and sales of modern traditional Chinese medicine, and is currently not involved in using AI for product development.
Shanghai Kaibao Pharmaceutical's Tareqing series products include Tareqing Injection and Tareqing Capsules.
Shanghai Kaibao Pharmaceutical (300039.SZ) stated on the investor interaction platform on June 12th that the Tanreqing series of products includes Tanreqing injection and Tanreqing capsules. The main efficacy of Tanreqing injection, which is the main product, is clearing heat, detoxifying, and resolving phlegm. It is mainly used for the treatment of acute and chronic bronchitis, pneumonia, and upper respiratory tract infections caused by bacteria or viruses. Tanreqing injection has been included in the prevention and control of "bird flu," "H1N1 flu," "H7N9 avian flu," "hand, foot, and mouth disease," "dengue fever," "Ebola," "Middle East Respiratory Syndrome," "COVID-19" and other diseases by the National Health Commission and Traditional Chinese Medicine.
Shanghai Kaibao (300039.SZ): The new land is currently being used for modern Chinese medicine intelligent manufacturing industrialization projects
Gelonghui May 11 丨 Shanghai Kaibao (300039.SZ) held a performance briefing on May 10, 2024, to discuss “Is buying land for synthetic organisms?” The company replied that the new land is currently being used for modern traditional Chinese medicine intelligent manufacturing industrialization projects, and future additions will be promptly disclosed.
Shanghai Kaibao (300039.SZ): Products under development are useful for synthetic biology technology
Gelonghui May 11 丨 Shanghai Kaibao (300039.SZ) held a performance briefing on May 10, 2024 to discuss “Your company has a biomedical concept, does it have synthetic biomedical products? Or are synthetic bio-health products being developed?” The company replied that the products it is developing are useful for synthetic biology technology.
No Data